Strategic partnerships Opportunity to expand through collaborations with government bodies and large employers, leveraging past free COVID-19 antibody testing initiatives and Meijer partnerships to deepen reach into corporate and public sector workplaces.

Expanded testing New quantitative testing capabilities for 7-Hydroxymitragynine and SARS-CoV-2 antibodies suggest a broader menu of oral fluid and serology assays that can appeal to clients requiring comprehensive compliance and workplace safety screening.

Near‑term growth Mid-sized firm with substantial revenue and a focused niche in oral fluid drug testing positions for upsell to existing clients and cross-sell additional testing services to healthcare providers and employers seeking rapid, tamper-proof results.

Technology alignment Current tech stack and modern web tools indicate capacity to support scalable digital onboarding, scheduling, and result delivery for enterprise customers, enabling streamlined sales motions and client communications.

Public health expertise Historical involvement in COVID-19 testing and antibody work enhances credibility with public sector purchasers and large organizations prioritizing employee health data, potentially unlocking RFP opportunities and long-term service contracts.